Russian Journal of AllergyRussian Journal of AllergyРоссийский Аллергологический Журнал1810-88302686-682XPublishing House ABV Press74310.36691/RJA743ArticlesСтатьиResearch ArticleMometasone furoate dry powder inhaler for the treatment of asthmaМометазона фуроат (Асманекс Твистхейлер) - новый ингаляционный глюкокортикоид для лечения бронхиальной астмыEmelyanovA VЕмельяновА Вemelav@inbox.ruGoryachkinaL AГорячкинаЛ АNorth-Western Medical University, St.-Petersburg, RussiaСеверо-Западный государственный медицинский университет им. И.И. МечниковаRussian Medical Academy for Postgradute StudiesРоссийская медицинская академия последипломного образования1508201294NO4 (2012)№4 (2012)798710032020Copyright ©; 2012, Pharmarus Print MediaCopyright ©; 2012, Фармарус Принт Медиа2012Pharmarus Print MediaФармарус Принт Медиаhttps://rusalljournal.ru/raj/article/view/743

The review is focused on inhaled mometasone furoate (Asmanex Twisthaler), a new medication for the treatment of asthma in adults and childred (12 years and older). Mometasone furoate (MF) has high antiinflammatory activity and low systemic bioavalability. MF has an excellent safety and efficacy profile in approved doses 200—800 mcg/daily od (in the evening) or bid (in the morning and in the evening). For patients with persistent asthma required treatment with an inhaled corticosteroid, MF is an excellent therapeutic choice.

Ингаляционные глюкокортикоиды занимают центральное место в лечении бронхиальной астмы (БА). Настоящий обзор посвящен новой лекарственной форме мометазона фуроата (МФ) для лечения астмы — Асманексу Твистхейлеру. Асманекс Твистхейлер является порошковым ингалятором, содержащим МФ и лактозу и предназначенным для лечения взрослых и детей (12 лет и старше в России). Из-за выраженного противовоспалительного потенциала МФ и его эффективной доставки в легкие препарат способен обеспечивать хороший контроль БА в относительно невысоких дозах (200—800 мкг/сут), применяемых 1 (вечером) или 2 раза (утром и вечером) в день. Риск системных побочных эффектов минимален из-за низкой биодоступности МФ. Это подтверждается результатами клинических исследований, в которых проводилось физикальное, лабораторное исследование, оценка функции гипоталамо-гипофизарно-надпочечниковой системы и скорости роста у детей. Частота местных побочных эффектов (осиплости голоса, сухости в горле, кандидоза) при ингаляционном применении МФ была низкой и сопоставимой с таковой у других ингаляционных глюкокортикоидов. Полученные данные свидетельствуют о высоком терапевтическом индексе МФ (т. е. соотношении эффективности и безопасности) у больных персистирующей астмой различной тяжести течения.

asthmainhaled corticosteroidsmometasone furoateбронхиальная астмаингаляционые глюкокортикоидымометазона фуроатGlobal Initiative for Аsthma. NHLB/WHO Workshop Report. National Heart Lung Blood Institute, Publication number 02-3659, revised 2006. Пер. с англ. под ред. А.Г. Чучалина. М., «Атмосфера». 2007, 103 с.Sharpe M., Jarvis B. Inhaled mometasone furoate. A review of its use in adults and adolescents with persistent asthma. Drugs. 2001, v. 61, p. 1325-1350.Chapman R.W., Sehring S.L., Gallisi C.G. et al. Anti-inflammatory activity of inhaled mometasone furoate in allergic mice. Arzneimittel Forshung. 1998, v. 48, p. 384-391.Barnes P. Optimizing the anti-inflammatory effects of corticosteroids. Eur. Respir. Rev. 2001, v. 11, p. 15-22.Pickering H., Pitcairn G.R., Hirst P.H. et al. Regional lung deposition of technetium 99m-labeled formulation of mometasone furoate administered by hydrofluoralkane 227 metered-dose inhaler. Clin. Ther. 2000, v. 22, p. 1483-1493.Affrime M.B., Cuss F., Padhi D. et al. Bioavailability and metabolism of mometasone furoate following administration by metered- dose and dry-powder inhalers in healthy volunteers. J. Clin. Pharm. 2000, v. 40, p. 1227-1236.Affrime M.B., Kosoglou T. The pharmacokinetics of mometasone furoate administered by dry powder inhaler following single and multiple dosing in patients with mild and moderate persistent asthma J. Allergy Clin. Immunol. 2001, v. 107, p. 104.Asmanex Twisthaler (mometasone furoate anhydrous dry powder inhaler). Clinical Monograph. USA. 2002, 93 р.Barnes P.J., Pedersen S. Busse W.W. Efficacy and safety of inhaled corticosteroids. New development. Am. J. Respir. Crit. Care Med.1998, v. 157 (3), p. 1-53.Kelly H.W. Establishing a therapeutic index for the inhaled corticosteroids: Part I. Pharmacokinetic/pharmacodinamic comparison of the inhaled steroids J. Allergy Clin. Immunol. 1998, v. 102 (4), p. 36-51.Pedersen S., O’Byrne P. A comparison of the efficaсy and safety of inhaled corticosteroids in asthma. Allergy. 1997, v. 52, suppl. 39, р. 1-34.Mometasone Furoate Dry Powder Inhaler. Expert report on pharmacotoxicological documentation. Schering Plough Ltd. 2000, p. 13-22.Shenkel E., Miller D., Angellini B. et al. Assessment of inspiratory flow rates and rise time data in patients with asthma. Ann. Allergy Asthma Immunol. 2000, v. 84, p. 158.Karpel J.P. An easy to use dry powder inhaler. Adv. Ther. 2000, v. 17, p. 283-287.Yang T.T., Li S., Wyka B., Kenyon D. Drug delivery performance of mometasone furoate dry powder inhaler. J. Aerosol. Med. 2001, v. 14, p. 487-494.Holgate S.T., Arshad H., Stryszak P., Harrison J.E. Mometasone furoate antagonizes AMP-induced bronchoconstriction in patients with mild asthma. J. Allergy Clin. Immunol. 2000, v. 105, p. 906-911.Inman M.D., Watson R.M., Rerecich T. et al. Dose-dependent effects of inhaled mometasone furoate on airway function and inflammation after allergen inhalation challenge. Am. J. Respir. Crit. Care Med. 2001, v. 164, p. 569-574.Nayak A.S., Banov C., Corren J. et al. Once daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma. Ann. Allergy Asthma Immunol. 2000, v. 84, p. 417-424.Kemp J.P., Berkowitz R.B., Miller S.D. et al. Mometasone furoate administered once daily is as effective as twice daily administration for treatment of mild to moderate persistent asthma. J. Allergy Clin. Immunol. 2000, v. 106, p. 485-492.Nayak A.S., Lampl K., Segall N., Harrison J.E. Long term use of once daily mometasone furoate is effective and well tolerated in patients with mild to moderate persistent asthma. Allergy Clin. Immunol. 2001, v. 107, p. 98Noonan M., Karpel J.P., Bensch G.W. et al. Comparison of once daily to twice daily treatment with mometasone furoate dry powder inhaler. Ann. Allergy Asthma Immunol. 2001, v. 86, p. 36-43.D’Urzo A., Karpell J.P., Busse W.W. et al. Efficacy and safety of mometasone furoate administered once daily in the evening in patients with persistent asthma dependent on inhaled corticosteroids. Current. Med. Res. Opinion. 2005, v. 21 (8), p. 1281-1289.Fish J.E., Karpel J.P., Craig T.J. et al. Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health related quality of life in patients with severe persistent asthma. J. Allergy Clin. Immunol. 2000, v. 106, p. 852-860.Karpel J., Nayak A., Lumry W. et al. Inhaled mometasone furoate reduces oral prednisone usage and improves lung function in severe persistent asthma. Respir. Med. 2007, v. 101, p. 628-637.Bernstein D.I., Berkowitz R., Chervinsky P. et al. Dose ranging study of new steroid for asthma: mometasone dry powder inhaler. Respir. Med. 1999, v. 93, p. 397-404.Bousquet J., D’Urso A., Herbert J. et al. Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler. Eur. Respir. J. 2000, v. 16, p. 808-816.Nathan R.A., Nayak A.S., Graft D.F. et al. Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate. Ann. Allergy Asthma Immunol. 2001, v. 86, p. 203-210.Corren J., Berkowitz R., Murray J. et al. Mometasone furoate 400 mcg once daily is more efficacious than budesonide 400 mcg once daily in improving asthma symptoms in patients with moderate persistent asthma. Eur. Respir. J. 2001, v. 17, 312 s.O’Connor B., Bonnaud G., Haahtela T. et al. Dose ranging study of persistent asthma using fluticasone propionate as an active comparator. Ann. Allergy Asthma Immunol. 2001, v. 86, p. 397-304.Affrime M.B., Kosoglou T., Thonoor C.M. et al. Mometasone furoate has minimal systemic side effects on hypothalamic-pituitary-adrenal axis when delivered at high doses. Chest. 2000, v. 118, p. 1538-1546.Murray J., Busse W., Dockhorn R. et al. Long term safety mometasone furiate (MF) administered by dry powder inhaler in patients with moderate persistent asthma. Eur. Respir. J. 2000, v. 16, p. 280-281.Raissy H.H., Blake K. Comparison of inhaled corticosteroids: what you need to know in choosing a product. Pediatric Allergy, Immunology and Pulmonology. 2011, v. 24 (3), p. 175-179.Milgrom H. Mometasone furoate in children with mild to moderate persistent asthma a review of the evidence. Pediatr. Drugs. 2010, v. 12, p. 213.Fausnight T.B., Craig T.J. Mometasone furoate dry powder inhaler for the treatment ofasthma. Expert. Opin. Pharmacother. 2011, v. 12 (17), p. 2707-2712.Friedman H.S., Navaratnam P., Mc Laughlin J. Adherence and asthma control with mometasone furoate versus fluticasone propionate in adolescents and young adults with mild asthma. J. Asthma. 2010, v. 47 (9), p. 994-1000.